폐암 (NSCLC)

30개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved30 programs
AntibodyLimited DatastaleLG ChemPhase 1

atezolizumab (Tecentriq, Phase 1b: LB-LR1109 and Atezolizumab)

Non-small Cell Lung Cancer(NSCLC); Head and Neck Squamous Cell Carcinoma(HNSCC) · Non-small Cell Lung Cancer(NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Phase1#monoclonal-antibody#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

QLS5132; Bevacizumab (QLS5132; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#monoclonal-antibody#Non-smallCellLungCancerNSCLC+1
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

QLS5132; Platinum; Bevacizumab (QLS5132; Platinum; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#monoclonal-antibody#Non-smallCellLungCancerNSCLC+1
Trials 1Status Recruiting
AntibodyLimited DatastaleAmsterdam UMC, location VUmcPhase 2

pembrolizumab (Keytruda, SABR + pembrolizumab)

NSCLC, Stage I · NSCLC, Stage I

#NSCLCStageI#Antibody#Phase2#monoclonal-antibody#NSCLC+2
Trials 1Status Active
AntibodyLimited DatastaleSanofiPhase 2

Tusamitamab ravtansine (SAR408701, SAR408701 (Tusamitamab ravtansine))

Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) · Non-squamous Non-small-cell Lung Cancer

#Non-squamousNon-small-cellLungCa#Antibody#Phase2#monoclonal-antibody#Sanofi
Trials 1Status Discontinued
AntibodyLimited DatastaleZibo Municipal HospitalPhase 2

SBRT combined with Tislelizumab followed by Tislelizumab (SBRT combined with Tislelizumab followed by Tislelizumab)

NSCLC; Tislelizumab · FRα

#FR#Antibody#Phase2#monoclonal-antibody#NSCLC+2
Trials 1Status Recruiting
AntibodyLimited DatastaleEli LillyPhase 2

Tunlametinib + Cetuximab β (Tunlametinib + Cetuximab β)

Lung Cancer (NSCLC) · Lung Cancer (NSCLC)

#LungCancerNSCLC#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Recruiting
AntibodyLimited DatastaleJiangsu Cancer Institute & Hosp…Phase 2

QL1706 (apalolimab and toripalimab, apalolimab and toripalimab (QL1706))

NSCLC; NSCLC (Non-small Cell Lung Cancer) · NSCLC

#NSCLC#Antibody#Phase2#monoclonal-antibody#NSCLCNon-smallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 3

anti-CTLA4 (tremelimumab, tremelimumab (anti-CTLA4))

Non - Small Cell Lung Cancer NSCLC · Non - Small Cell Lung Cancer NSCLC

#Non-SmallCellLungCancerNSCLC#Antibody#Phase3#monoclonal-antibody#AstraZeneca
Trials 1Status Active
AntibodyLimited DatastalePartner Therapeutics, Inc.Phase 2

MCLA-128 (zenocutuzumab, zenocutuzumab (MCLA-128))

Solid Tumours Harboring NRG1 Fusion; NSCLC Harboring NRG1 Fusion · Solid Tumours Harboring NRG1 Fusion

#SolidTumoursHarboringNRG1Fusion#Antibody#Phase2#monoclonal-antibody#NSCLCHarboringNRG1Fusion+1
Trials 1Status Recruiting

2 / 2 pages

← PreviousNext →